84 filings
Page 2 of 5
SC TO-T
pu5 fgc2en
10 Jan 24
Third party tender offer statement
8:51am
SC14D9C
yy9b7kg 4wc0x
22 Dec 23
Written communication relating to third party tender offer
6:52am
8-K
m86uzsh v3f6ihmd
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
8btf1ks qqc
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
gbj7v
27 Nov 23
Other Events
6:37am
NT 10-Q
qdcx0b
15 Nov 23
Notice of late quarterly filing
7:00am
8-K
fzdje9u2cnltvwro4k9
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
8-K
8fly9
31 Oct 23
Termination of a Material Definitive Agreement
4:13pm
8-K
zo9dvbhz
10 Aug 23
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
7:05am
8-K
diikw
13 Jul 23
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
4:08pm
8-K
7n9vy
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:32pm
8-K
llhsr btsb2k
25 May 23
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
5:04pm
8-K
yras9boai
11 May 23
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
7:09am
ARS
4ujmtqhr7uw
26 Apr 23
Annual report to shareholders
9:03am
DEFA14A
vh6tnt off3n
26 Apr 23
Additional proxy soliciting materials
9:01am
PRE 14A
xgkm800zi7i6qs7l
14 Apr 23
Preliminary proxy
9:00am